Natera, Inc. (ntra)
NTRA Estimates
Public analyst price targets and consensus snapshot for Natera, Inc.. Deeper estimate history and models are available in Vest Terminal.
| Last price | $390.79 |
| Analyst mean target | $348.02 |
| Analyst high target | $435.00 |
| Analyst low target | $280.00 |
| Upside vs mean target | -10.9% |
| Consensus recommendation | Strong Buy |
| Number of analysts | 23 |
| Forward P/E | -3751.82 |
Start Free — open NTRA in Vest Terminal
Access live data, filings, ownership, and analysis for Natera, Inc..
Natera, Inc. FAQ
What does Natera, Inc. (NTRA) do?
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients p…
What is NTRA's P/E ratio?
Natera, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does NTRA pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is NTRA in?
Natera, Inc. is classified in Healthcare (Diagnostics & Research) on NMS.
What is NTRA's market capitalization?
Approximate market cap: $56.33B.
What are the main risks for NTRA?
Key risks include above-average volatility (beta 1.53), among factors on this page.
What are the strengths of NTRA?
Potential positives include revenue growth of 37.7% year-over-year, gross margin of 65.2% supports competitive unit economics.
Where can I get analyst estimates for NTRA?
Public analyst price targets and consensus for Natera, Inc. are on the free /stocks/ntra/estimates page. Deeper estimate history and models are available in Vest Terminal.